However, in 2021 [117], they observed no significant difference in MMP2 expression in the analysis of large numbers of ccRCC clinical samples and normal kidney tissue, and no RCC prognosis association [118], indicating that G6PD-mediated ccRCC progression may be dependent on other more critical underlying mechanisms. The gene discussed is MMP2; the disease is renal cell carcinoma.